JP2013509433A5 - - Google Patents

Download PDF

Info

Publication number
JP2013509433A5
JP2013509433A5 JP2012537128A JP2012537128A JP2013509433A5 JP 2013509433 A5 JP2013509433 A5 JP 2013509433A5 JP 2012537128 A JP2012537128 A JP 2012537128A JP 2012537128 A JP2012537128 A JP 2012537128A JP 2013509433 A5 JP2013509433 A5 JP 2013509433A5
Authority
JP
Japan
Prior art keywords
virus
compound
pharmaceutically acceptable
acceptable salt
oral administration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2012537128A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013509433A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2010/054779 external-priority patent/WO2011053812A1/en
Publication of JP2013509433A publication Critical patent/JP2013509433A/ja
Publication of JP2013509433A5 publication Critical patent/JP2013509433A5/ja
Pending legal-status Critical Current

Links

JP2012537128A 2009-10-30 2010-10-29 ウイルス関連疾患を処置する方法 Pending JP2013509433A (ja)

Applications Claiming Priority (31)

Application Number Priority Date Filing Date Title
US25670109P 2009-10-30 2009-10-30
US61/256,701 2009-10-30
US32698910P 2010-04-22 2010-04-22
US32698610P 2010-04-22 2010-04-22
US32698210P 2010-04-22 2010-04-22
US32699110P 2010-04-22 2010-04-22
US61/326,986 2010-04-22
US61/326,982 2010-04-22
US61/326,989 2010-04-22
US61/326,991 2010-04-22
US32747410P 2010-04-23 2010-04-23
US61/327,474 2010-04-23
US32791410P 2010-04-26 2010-04-26
US61/327,914 2010-04-26
US32849110P 2010-04-27 2010-04-27
US61/328,491 2010-04-27
US33062410P 2010-05-03 2010-05-03
US61/330,624 2010-05-03
US33170410P 2010-05-05 2010-05-05
US61/331,704 2010-05-05
US35543010P 2010-06-16 2010-06-16
US61/355,430 2010-06-16
US40507510P 2010-10-20 2010-10-20
US40508010P 2010-10-20 2010-10-20
US40507310P 2010-10-20 2010-10-20
US40508410P 2010-10-20 2010-10-20
US61/405,075 2010-10-20
US61/405,084 2010-10-20
US61/405,073 2010-10-20
US61/405,080 2010-10-20
PCT/US2010/054779 WO2011053812A1 (en) 2009-10-30 2010-10-29 Methods of treating viral associated diseases

Publications (2)

Publication Number Publication Date
JP2013509433A JP2013509433A (ja) 2013-03-14
JP2013509433A5 true JP2013509433A5 (cg-RX-API-DMAC7.html) 2013-12-19

Family

ID=43922582

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2012537128A Pending JP2013509433A (ja) 2009-10-30 2010-10-29 ウイルス関連疾患を処置する方法

Country Status (6)

Country Link
US (2) US20130072458A1 (cg-RX-API-DMAC7.html)
EP (1) EP2493479A4 (cg-RX-API-DMAC7.html)
JP (1) JP2013509433A (cg-RX-API-DMAC7.html)
AU (1) AU2010313273B2 (cg-RX-API-DMAC7.html)
CA (1) CA2779473C (cg-RX-API-DMAC7.html)
WO (1) WO2011053812A1 (cg-RX-API-DMAC7.html)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006110655A2 (en) 2005-04-08 2006-10-19 Chimerix, Inc. Compounds, compositions and methods for the treatment of poxvirus infections
CN105055432A (zh) 2008-01-25 2015-11-18 奇默里克斯公司 治疗病毒感染的方法
US8614200B2 (en) 2009-07-21 2013-12-24 Chimerix, Inc. Compounds, compositions and methods for treating ocular conditions
CA2789443C (en) 2010-02-12 2016-09-13 Chimerix, Inc. Nucleoside phosphonate salts
EP2563367A4 (en) * 2010-04-26 2013-12-04 Chimerix Inc Methods of treating retroviral infections and related dosage regimes
CN105998039A (zh) * 2010-08-31 2016-10-12 奇默里克斯公司 膦酸酯衍生物及其合成方法
US20140303092A1 (en) * 2011-10-26 2014-10-09 Chimerix, Inc Hexadecyloxypropyl cidofovir for the treatment of double-stranded dna virus infection
CA2857490C (en) 2011-12-22 2020-03-31 Geron Corporation Guanine analogs as telomerase substrates and telomere length affectors
WO2013163509A1 (en) * 2012-04-27 2013-10-31 Chimerix, Inc. A method of mitigating virus associated end-organ damage
CN107312039B (zh) 2012-08-30 2019-06-25 江苏豪森药业集团有限公司 一种替诺福韦前药的制备方法
US9526729B2 (en) * 2013-01-29 2016-12-27 Hsiao Lily Yu Medicament for treating peripheral neuropathies
KR20150130355A (ko) 2013-03-15 2015-11-23 더 리전트 오브 더 유니버시티 오브 캘리포니아 비환식 뉴클레오사이드 포스포네이트 디에스테르
UA116825C2 (uk) 2013-11-15 2018-05-10 Чимерикс Інк. Морфологічні форми гексадецилоксипропілових складних ефірів фосфонової кислоти і способи їх синтезу
MX377983B (es) 2014-09-15 2025-03-04 Univ California Análogos de nucleótidos.
US10160778B2 (en) 2014-10-27 2018-12-25 Concert Pharmaceuticals, Inc. Pyrimidine phosphonic acid esters
EP3875462A1 (en) 2015-09-15 2021-09-08 The Regents of The University of California Nucleotide analogs
WO2017196990A1 (en) * 2016-05-12 2017-11-16 Contravir Pharmaceuticals, Inc. Methods of treating hepatitis b infections and related dosage regimes
AU2017290703B2 (en) 2016-06-28 2023-03-30 Emergent Biodefense Operations Lansing Llc Formulations of brincidofovir
WO2018156879A1 (en) * 2017-02-23 2018-08-30 Chimerix, Inc. Treatment of adenovirus with brincidofovir
WO2020138067A1 (ja) * 2018-12-25 2020-07-02 富士フイルム富山化学株式会社 ピラジン誘導体と細胞内におけるピラジン誘導体リボース三リン酸体の量を増加させる化合物とを組み合わせてなるrnaウイルス感染症治療剤
EP3946402A1 (en) * 2019-03-29 2022-02-09 Evonik Operations GmbH Preparations containing berry extracts for use in the prophylaxis and/or treatment of viral infections caused by herpesviridae
CN117285565A (zh) * 2022-06-24 2023-12-26 润佳(苏州)医药科技有限公司 核苷类似物及其医药用途
KR20250052378A (ko) 2022-07-21 2025-04-18 안티바 바이오사이언시즈, 인크. Hpv 감염 및 hpv-유도 신생물의 치료를 위한 조성물 및 투여 형태
JP7417339B1 (ja) 2023-08-07 2024-01-18 シンバイオ製薬株式会社 アデノウイルス感染又はアデノウイルス感染に伴う疾患の治療

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6605602B1 (en) * 2001-09-28 2003-08-12 University Of Pittsburgh-Of The Commonwealth System Of Higher Education Method of treating BK virus nephropathy
TW200408645A (en) * 2002-04-26 2004-06-01 Gilead Sciences Inc Non nucleoside reverse transcriptase inhibitors
US20050261237A1 (en) * 2003-04-25 2005-11-24 Boojamra Constantine G Nucleoside phosphonate analogs
US20070292523A1 (en) * 2004-09-27 2007-12-20 Joey Moodley Dihydropyrimidine Formulations
WO2006110655A2 (en) * 2005-04-08 2006-10-19 Chimerix, Inc. Compounds, compositions and methods for the treatment of poxvirus infections
WO2008118013A2 (en) * 2007-03-23 2008-10-02 To-Bbb Holding B.V. Targeted intracellular delivery of antiviral agents
CN101678122A (zh) * 2007-04-27 2010-03-24 奇默里克斯公司 在核苷给药的受体中降低肾中毒性的方法
WO2011017253A1 (en) * 2009-08-03 2011-02-10 Chimerix, Inc. Composition and methods of treating viral infections and viral induced tumors
US20110263536A1 (en) * 2010-04-22 2011-10-27 Chimerix, Inc. Methods of Treating Orthopox Virus Infections and Associated Diseases

Similar Documents

Publication Publication Date Title
JP2010525063A5 (cg-RX-API-DMAC7.html)
Kim et al. Coinfection with HIV-1 and HCV—a one-two punch
De Clercq Antivirals: past, present and future
RU2015141024A (ru) Производные эфиров фосфоновых кислот и способы их синтеза
De Clercq et al. Antiviral potential of a new generation of acyclic nucleoside phosphonates, the 6-[2-(phosphonomethoxy) alkoxy]-2, 4-diaminopyrimidines
JP2016515128A5 (cg-RX-API-DMAC7.html)
AU2010313273B2 (en) Methods of treating viral associated diseases
JP2017520594A5 (cg-RX-API-DMAC7.html)
Speth et al. HIV-infection of the central nervous system: the tightrope walk of innate immunity
JP2013503882A5 (cg-RX-API-DMAC7.html)
JP2014527995A5 (cg-RX-API-DMAC7.html)
US20160143884A1 (en) Use of tetrahydroindazolylbenzamide and tetrahydroindolylbenzamide derivatives for the treatment of human immunodeficiency virus (hiv) and acquired immune deficiency syndrome (aids)
JP2014526508A5 (cg-RX-API-DMAC7.html)
GB2544439B (en) Antiviral composition
Bourliere et al. HBsAg clearance after addition of 48 weeks of PEGIFN in HBeAg negative CHB patients on Nucleos (t) ide therapy with undetectable HBV DNA for at least one year: a multicenter randomized controlled phase III trial ANRS-HB06 PEGAN study: preliminary findings: 1863
JP2002531495A5 (cg-RX-API-DMAC7.html)
Santos et al. Human herpes virus: types, oral manifestations and treatment
Lou et al. EFFICACY OF ORAL VALGANCICLOVIR IN THE TREATMENT OF CYTOMEGALOVIRUS INFECTION IN RENAL TRANSPLANT RECIPIENTS.
Salvador et al. EFFICACY AND SAFETY OF ORAL VALGANCICLOVIR TREATMENT OF CYTOMEGALOVIRUS INFECTION AFTER A SHORT INDUCTION WITH GANCICLOVIR IV IN SOLID ORGAN TRANSPLANTATION.
JP2007516296A5 (cg-RX-API-DMAC7.html)
WO2025105377A1 (ja) Epstein-Barrウイルス複製阻害剤
Jacobs Elevated aminotranferases levels: case report
Georgiev Herpesviruses
JP2024523429A5 (cg-RX-API-DMAC7.html)
Biswas et al. Isolation and characterization of an helicase-primase inhibitor (HPI)-resistant HSV-1 mutant in tissue culture and a mouse-skin model